Newbury Pharmaceuticals

Newbury Pharmaceuticals Secures Generic Approval for Liraglutide Pre-Filled Pen

Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Liraglutide pre-filled pen in Denmark as the first country in a Scandinavian registration procedure. Approvals in Sweden and Norway are expected to follow upon finalized national reviews.

Liraglutide pre-filled pen, a GLP-1 peptide drug that will be marketed under the brand name Milmiga®, is a bioequivalent version of Victoza pre-filled pen, indicated for the treatment of type 2 diabetes. Victoza achieved sales exceeding €27 million in Scandinavia, as reported by DLMI. 

“The successful approval of Liraglutide highlights our capability to offer a diverse and comprehensive portfolio, encompassing both complex peptide injectables and small molecule oral treatments.” says Mr Lars Minor CEO of Newbury
Datum 2024-06-20, kl 13:00
Källa MFN
Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.